{"nctId":"NCT00440466","briefTitle":"PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients","startDateStruct":{"date":"2007-07"},"conditions":["Anemia","Renal Diseases"],"count":430,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: epoetin alfa"]},{"label":"003","type":"EXPERIMENTAL","interventionNames":["Drug: epoetin alfa"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: epoetin alfa"]}],"interventions":[{"name":"epoetin alfa","otherNames":[]},{"name":"epoetin alfa","otherNames":[]},{"name":"epoetin alfa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet the diagnostic criteria for chronic kidney disease, defined as a glomerular filtration rate (GFR) \\>=15 mL/min per 1.73 m2 and \\<60 mL/min per 1.73 m2 (Stages 3 and 4) as calculated by the central laboratory\n* Hemoglobin level between 10.0 and 11.9 g/dL during the 4 weeks before randomization\n* History of increase in hemoglobin after the initial dose\n* Stable dose of epoetin alfa given once-weekly before randomization.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension\n* Iron deficiency\n* iron overload\n* severe congestive heart failure\n* Active infection\n* Recent heart attack, Stroke or blood clot.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin Concentration in Grams Per Deciliter (g/dL) From Baseline to the Average of the Last 12 Weeks of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.728"},{"groupId":"OG001","value":"-0.10","spread":"0.774"},{"groupId":"OG002","value":"-0.19","spread":"0.738"}]}]}]},{"type":"SECONDARY","title":"Proportion of Weeks Per Patient With Hemoglobin Concentration Between 10.0 and 11.9 Grams Per Deciliter (g/dL)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":null},{"groupId":"OG001","value":"0.88","spread":null},{"groupId":"OG002","value":"0.83","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Who Exceeded a Hemoglobin Concentration of 11.9 Grams Per Deciliter (g/dL)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"161","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Maximum Hemoglobin Concentration in Grams Per Deciliter (g/dL)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.35","spread":"0.828"},{"groupId":"OG001","value":"12.48","spread":"0.760"},{"groupId":"OG002","value":"12.46","spread":"0.988"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Who Met or Exceeded 1.0 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"191","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Who Met or Exceeded 1.5 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"124","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Who Met or Exceeded 2.0 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Maximum Hemoglobin Rate of Rise in Grams Per Deciliter (g/dL/2 Weeks)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":"1.068"},{"groupId":"OG001","value":"1.69","spread":"0.790"},{"groupId":"OG002","value":"1.81","spread":"1.173"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Died","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":108},"commonTop":["Hypertension","Oedema","Urinary tract infection","Hyperkalaemia","Oedema peripheral"]}}}